Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity Transactions - Additional Information (Detail)

v3.10.0.1
Equity Transactions - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Dec. 10, 2018
Dec. 30, 2015
Aug. 31, 2018
Aug. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares issued in transaction     11,300,000      
Sale of stock, price per share (in dollars per share)     $ 12.75      
Proceeds from issuance of common stock     $ 143.7      
Sale of stock, consideration received     135.1      
Payments of stock issuance costs     $ 8.6      
Preferred stock, shares outstanding         0 6,864,000
Genoptix            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock issued (in shares) 1,000,000          
Genoptix | Restricted Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock issued (in shares) 1,000,000.0          
Clarient Inc            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock issued (in shares)   15,000,000.0        
Clarient Inc | Payment In Kind            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Preferred stock dividends issued (in shares)         300,000  
Clarient Inc | Series A Redeemable Convertible Preferred Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock issued (in shares)   14,700,000        
Shares redeemed during period           8,100,000
Preferred stock, shares outstanding         6,900,000 6,600,000
Ascend Genomics            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Issuance of restricted stock (in shares)       500,000